retifanlimab (Zynyz)
Jump to navigation
Jump to search
Indications
- metastatic or recurrent locally advanced Merkel cell carcinoma
Mechanism of action
- targets checkpoint inhibitor PD-1
- blocks PD-1 interaction with PD-1 ligands PD-L1 & PD-L2
- suppresses tumor growth
More general terms
References
- ↑ Grignani G et al 545 A phase 2 study of retifanlimab in patients with advanced or metastatic merkel cell carcinoma (MCC) (POD1UM-201) Journal for ImmunoTherapy 2023, 9(S2) Not indexed in PubMed https://jitc.bmj.com/content/9/Suppl_2/A574